918博天堂(中华区)官方网站

Article Publication | Huaota HB0017 (IL-17A Monoclonal Antibody) Phase I Clinical Study Published

Abstract:Recently, Dr. Yongmin Yang, Vice General Manager of Clinical Research at Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota"), publis...

Press Releases

China’s first CD73-targeting antibody cocktail HB0045 has been administered to its first patient in the United States

SUMMARYShanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") recently announced that the company's independently developed HB0045 project, ...

Press Releases

Huaota will present promising result of HB0034 at the 32nd EADV

The much-anticipated 32nd EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) will be held in Berlin, Germany, from October 11 to 14, 2023. The EADV Congress is one of the larges...

Press Releases

IND of HB0036 Approved by FDA

Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") received FDA approval for the anti-PD-L1/TIGIT bispecific antibody (project code HB0036),...

Press Releases

Huaota Announces HB0030 Has Completed the First-in-human Administration

Shanghai, China, Dec 24 2021 --- Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) announced that HB0030 (anti-TIGIT monoclonal antibody) completed the first-in-human administrat...

Press Releases

FDA Accepts IND Application of HB0036 from Huaota

Shanghai, 17 Dec 2021 – Shanghai Huaota Biopharmaceutical Co., Ltd (“Huaota”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New D...

Press Releases